RPB

Oxytocin

OT, OXT, Pitocin, Syntocinon (brand names of the approved medicine), oxytocin acetate; intranasal research sprays

Longevity & cellular
Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates
Note on this profile. Oxytocin is an approved prescription medicine everywhere for inducing or augmenting labour and controlling bleeding after birth, given intravenously or intramuscularly under monitoring in hospital. Intranasal oxytocin for social, sexual or psychiatric purposes is an active research area but is not approved anywhere, and the compounded nasal sprays and lyophilised vials used in the community are unapproved. This page explains the published science for both.

1What it is

Oxytocin is a hormone the body makes in the hypothalamus. It is released into the blood from the pituitary during childbirth and breastfeeding, and into the brain during social contact, touch and orgasm. Its structure was worked out and it was synthesised in 1953 by Vincent du Vigneaud — the first peptide hormone ever made in the laboratory, which earned him the 1955 Nobel Prize. Pharmaceutical oxytocin (Pitocin, Syntocinon) has been used in delivery rooms since the 1950s and is on the WHO Essential Medicines list.

Interest in its brain effects took off after 2005, when a single intranasal dose was reported to increase trust in an economic game (Kosfeld 2005), followed by hundreds of studies in autism, schizophrenia, anxiety, PTSD, depression, obesity and sexual function. Many early findings have not replicated, and the field has become a case study in small-sample, positive-publication bias. The oxytocin used in research and community nasal sprays is the same molecule as the obstetric drug.

2How it's thought to work

Uterus and breast. binds oxytocin receptors on uterine smooth muscle, causing rhythmic contractions whose strength depends on how many receptors the uterus has (which rises sharply late in pregnancy); contracts myoepithelial cells around milk ducts for the let-down reflex.
Brain. oxytocin neurons project to the amygdala, nucleus accumbens, hippocampus and brainstem. Proposed effects include increased attention to social cues and eye contact, reduced amygdala reactivity to threat, dampened cortisol responses to stress, enhanced reward from social contact, and effects on sexual arousal and orgasm. Effects depend heavily on context and the individual — it can heighten in-group favouritism or envy as well as trust.
Does nasal oxytocin reach the brain?. Studies show CSF levels rise after intranasal dosing in humans and monkeys, likely via olfactory and trigeminal routes, but how much reaches relevant regions, and whether blood-borne oxytocin contributes, remains debated (Leng & Ludwig 2016).
Vasopressin receptors. at high doses oxytocin also acts on vasopressin receptors, with effects on blood pressure and water retention.
Released from the posterior pituitary: it contracts the uterus and milk ducts, and in the brain it shapes social attention and bonding.Schematic — not to scale

3What the research shows

Labour induction and augmentation

Standard of care, supported by Cochrane reviews; IV oxytocin shortens labour and reduces caesarean rates in certain contexts, with uterine hyperstimulation as the main risk (Alfirevic 2009, Cochrane; Budden 2014, Cochrane — high- vs low-dose regimens).

Prevention and treatment of postpartum haemorrhage

First-line uterotonic worldwide; 10 IU IM reduces blood loss and need for transfusion (Westhoff 2013, Cochrane). Heat-stable carbetocin is a longer-acting analogue used where refrigeration is limited (Widmer 2018, NEJM — WHO CHAMPION trial). [11][12]
Graded A (largely negative)

Autism spectrum disorder (intranasal, chronic)

Early small trials suggested improved social responsiveness. The largest trial — 290 children and adolescents given 24–80 IU/day for 24 weeks — found no benefit over placebo on social function (Sikich 2021, NEJM). Meta-analyses report small, inconsistent effects at best. [4]
Graded A (mixed/negative)

Schizophrenia (adjunctive, intranasal)

Several ; pooled analyses show no consistent improvement in symptoms or social cognition (Williams & Bürkner 2017, Schizophr Res — meta-analysis). [5]
Graded B/A (replication problems)

Trust, social cognition, emotion recognition in healthy adults

The original trust-game finding (Kosfeld 2005, Nature) failed direct replication (Nave 2015, Perspect Psychol Sci — review). Many single-dose studies with 20–60 participants report effects on emotion recognition or eye gaze; pre-registered larger studies often find none. Treat the behavioural literature as unsettled. [2][3]
Graded A/B (mixed)

Anxiety, PTSD, depression, postpartum depression

Small RCTs show reduced cortisol and anxiety in some stress paradigms and some PTSD symptom reduction when given soon after trauma (van Zuiden 2017, Biol Psychiatry), but also null and negative results. Postpartum depression trials have been negative or showed worsened mood in some.
Graded B (small, mixed)

Sexual function and orgasm

Intranasal oxytocin before intercourse in couples improved some aspects of sexual experience vs placebo in one 22-couple crossover, though the placebo effect was large (Behnia 2014, Horm Behav); in women with sexual dysfunction it did not outperform placebo (Muin 2015, Fertil Steril). Small studies report increased orgasm intensity in men and women; others report no change. Case reports exist of benefit in anorgasmia. [8][9]

Appetite and weight

Single doses reduced caloric intake in small crossover studies in men (Lawson 2015, Obesity); an 8-week trial in adults with obesity did not reduce weight (Plessow 2024, JAMA Netw Open †). [10]

Lactation (nasal Syntocinon spray)

Historical use to aid milk let-down; Cochrane found insufficient evidence (Renfrew 2000) and the spray was withdrawn in most markets.

4Reported side effects and interactions

Literature-reported

Literature (obstetric IV/IM). uterine hyperstimulation and foetal distress, uterine rupture (rare), postpartum haemorrhage from uterine atony after prolonged infusion, nausea, vomiting, arrhythmias, hypotension with rapid IV bolus, and water intoxication (hyponatraemia, seizures) with prolonged high-dose infusion because of its vasopressin-like action. US labelling carries a boxed warning restricting use to medical induction, not elective.

Literature (intranasal research). generally well tolerated in thousands of research participants; nasal irritation, headache, transient light-headedness, calmness or drowsiness, occasional increased anxiety or irritability; no serious adverse events attributed in meta-analyses (MacDonald 2011, Psychoneuroendocrinology — safety review). Chronic trials in autism up to 24 weeks reported increased appetite, thirst and urination, irritability and sedation more often than placebo.

Community-reported

warmth and calm, increased emotional openness or tearfulness, enhanced orgasm, drowsiness, headache, nasal irritation, occasionally heightened anxiety or feeling "flat" the next day; sublingual users report little effect, consistent with poor oral bioavailability.

Theoretical. in pregnancy oxytocin can cause uterine contractions — intranasal use during pregnancy is not safe; effects on bonding and social judgement are context-dependent and not uniformly positive; chronic dosing may down-regulate receptors (animal data); unknown effects in adolescents' developing social brain, though trials in children have not shown harm. Compounded sprays vary in potency and degrade with heat.

Interactions. vasoconstrictors and sympathomimetics (including those in some anaesthetics) can cause severe hypertension with oxytocin; prostaglandins (misoprostol, dinoprostone) potentiate uterine effects; cyclopropane anaesthesia and inhalational agents alter cardiovascular response; alcohol and MDMA (which itself releases oxytocin) have additive effects in community reports.

Markers researchers commonly monitor

MarkerWhy it's watched
Blood pressure and heart ratehypotension with rapid IV dosing, hypertension with sympathomimetics; a baseline is sensible for any route.
Serum sodiumoxytocin's vasopressin-like action can cause hyponatraemia with high or prolonged dosing; chronic intranasal trials report increased thirst and urination.
Mood and anxiety ratingsthe behavioural outcome of interest, and because paradoxical anxiety is reported.
Pregnancy statusoxytocin contracts the uterus; confirm before any non-obstetric use in women of reproductive age.
Cortisol (salivary)the stress-axis marker most often used in research.
Plasma oxytocin itself is rarely useful: assays are unreliable and blood levels do not reflect brain levels (McCullough 2013)
No other compound-specific blood markers are established; general baselines (CBC, CMP) otherwise

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Approved ampoules and vials (10 IU/ml) need no preparation and are used under medical supervision. Compounded nasal sprays are usually 10–40 IU per 0.1 ml spray; oxytocin acetate vials (commonly 2 mg ≈ ~1,000 IU, by the ~500 IU/mg conversion †) are with for nasal or use. Oxytocin is unstable at room temperature over weeks — keep refrigerated, protect from light, and discard if the solution yellows. Doses are in international units; the calculator supports IU conversion.

Open in calculator, pre-loaded →

6Commonly studied alongside

Behavioural therapy (autism and social-anxiety trials); antipsychotics (adjunctive trials); MDMA-assisted therapy research (as a mechanism, not a co-treatment); PT-141 and kisspeptin (parallel sexual-function research lines, not combined in trials); vasopressin (comparator hormone); carbetocin and atosiban (long-acting agonist and antagonist analogues).

Informational cross-links. Not stack recommendations.

7Regulatory status by region

RegionStatus (checked —)
United StatesFDA-approved (Pitocin and generics) for labour induction/augmentation and postpartum bleeding; prescription-only. Intranasal and compounded oxytocin for behavioural use is unapproved; compounding availability varies †
European UnionAuthorised nationally (Syntocinon and generics) for obstetric indications; nasal Syntocinon spray withdrawn from most markets
United KingdomMHRA-licensed (Syntocinon) for obstetric use; prescription-only
AustraliaTGA-registered (Syntocinon, Oxytocin injection); Schedule 4
South AfricaSAHPRA-registered (Syntocinon and generics); prescription-only
Sport (WADA)Not on the Prohibited List as of review date †

8Open questions

  • How much intranasal oxytocin reaches the brain, and whether the dose–response is linear or inverted-U as some data suggest.
  • Why early positive behavioural findings failed to replicate: publication bias, small samples, or genuine context-dependence?
  • Any durable clinical benefit in autism, schizophrenia, PTSD or sexual dysfunction — current large trials are mostly negative.
  • Safety of chronic intranasal use beyond 6 months; receptor down-regulation seen in animals.

9References

  1. 1du Vigneaud V et al. (1953). The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. PubMed
  2. 2Kosfeld M et al. (2005). Oxytocin increases trust in humans. Nature. PubMed · DOI
  3. 3Nave G, Camerer C, McCullough M (2015). Does oxytocin increase trust in humans? A critical review of research. Perspect Psychol Sci. PubMed · DOI
  4. 4Sikich L et al. (2021). Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med. PubMed · DOI
  5. 5Williams DR, Bürkner PC (2017). Effects of intranasal oxytocin on symptoms of schizophrenia: a multivariate Bayesian meta-analysis. Psychoneuroendocrinology. PubMed · DOI
  6. 6MacDonald E et al. (2011). A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. PubMed · DOI
  7. 7Leng G, Ludwig M (2016). Intranasal oxytocin: myths and delusions. Biol Psychiatry. PubMed · DOI
  8. 8Behnia B et al. (2014). Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Horm Behav. PubMed · DOI
  9. 9Muin DA et al. (2015). Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial. Fertil Steril. PubMed · DOI
  10. 10Lawson EA et al. (2015). Oxytocin reduces caloric intake in men. Obesity (Silver Spring). PubMed · DOI
  11. 11Westhoff G, Cotter AM, Tolosa JE (2013). Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev. PubMed · DOI
  12. 12Widmer M et al. (2018). Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. PubMed · DOI
  13. 13McCullough ME, Churchland PS, Mendez AJ (2013). Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci Biobehav Rev. PubMed · DOI
  14. 14Pitocin (oxytocin injection) US prescribing information (current label). PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

0
forum threads →
0
community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

25 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.